Lin; Powei

Patent Applications and Registrations

Patent applications and USPTO patent grants for Lin; Powei.The latest application filed is for "combination therapy using dual inhibitor of c-met and egfr and igf-1r inhibitor".

Company Profile

0.10.11

Lin; Powei - Hwaseong-si KR
Lin; Powei - Hwaseongi-si KR
Lin; Powei - Gyeonggi-do KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bispecific anti-Cmet/anti-Her2 antibodies Grant 10,143,749 - Cho , et al. De	2018-12-04
Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof Grant 10,000,569 - Cheong , et al. June 19, 2	2018-06-19
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same Grant 9,975,960 - Cho , et al. May 22, 2	2018-05-22
Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor Grant 9,943,596 - Lee , et al. April 17, 2	2018-04-17
Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same Grant 9,902,776 - Cho , et al. February 27, 2	2018-02-27
Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor Grant 9,730,926 - Lin , et al. August 15, 2	2017-08-15
Anti-c-Met/anti-EGFR bispecific antibodies Grant 9,657,104 - Cho , et al. May 23, 2	2017-05-23
Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same Grant 9,505,843 - Kim , et al. November 29, 2	2016-11-29
Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins Grant 9,499,622 - Cheong , et al. November 22, 2	2016-11-22
Bispecific chimeric proteins comprising DARPins Grant 9,359,440 - Cheong , et al. June 7, 2	2016-06-07
Combination Therapy Using Dual Inhibitor Of C-met And Egfr And Igf-1r Inhibitor App 20160144028 - Lee; Jimin ; et al.	2016-05-26
Anti-her2 Antibody And Anti-c-met/anti-her2 Bispecific Antibodies Comprising The Same App 20150322162 - CHO; Mi Young ; et al.	2015-11-12
Anti-cmet/anti-egfr/anti-her3 Multipecific Antibodies And Use Thereof App 20150322165 - Cheong; Kwang Ho ; et al.	2015-11-12
Anti-egfr/anti-her2 Bispecific Antibodies With Anti-egfr Darpins App 20150232573 - Cheong; Kwang Ho ; et al.	2015-08-20
Combination Therapy Using Bispecific Anti-c-met/anti-egfr Antibody And C-src Inhibitor App 20150216972 - Lin; Powei ; et al.	2015-08-06
Anti-her3 Scfv Fragment And Bispecific Anti-c-met/anti-her3 Antibodies Comprising The Same App 20150210766 - KIM; Min-Kyung ; et al.	2015-07-30
BISPECIFIC CHIMERIC PROTEINS WITH DARPins App 20150030596 - CHEONG; Kwang Ho ; et al.	2015-01-29
Anti-egfr Antibody And Anti-c-met/anti-egfr Bispecific Antibodies Comprising The Same App 20150030599 - CHO; Mi Young ; et al.	2015-01-29
Anti-c-met/anti-egfr Bispecific Antibodies App 20140302029 - CHO; MI YOUNG ; et al.	2014-10-09
Bispecific Anti-cmet/anti-her2 Antibodies App 20140294838 - CHO; Mi Young ; et al.	2014-10-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.